Related Experiment Video
Updated: Sep 12, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Complex Interplay Between Estrogen and Aging via Lipid Metabolism and Inflammation Forms the Novel Treatment
Yijun Xin1, Zhaoji Yuan2, Jianxu Wang3
1Metabolism and Disease Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Insights
This review explores how estrogen levels and aging interact to drive atherosclerosis (AS). Combining aging interventions with tailored estrogen therapy may offer new treatments for cardiovascular disease.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Gerontology
Background:
- Atherosclerosis (AS) is a major cause of cardiovascular and cerebrovascular events.
- Estrogen levels and aging are key factors in AS development, influencing lipid metabolism and inflammation.
- A bidirectional loop exists between estrogen deficiency, vascular senescence, and aging.
Purpose of the Study:
- To analyze the complex interplay between estrogen, aging, and AS pathogenesis.
- To identify potential therapeutic strategies for managing age-related atherosclerosis.
- To explore how sex-specific aging influences the estrogen-AS relationship.
Main Methods:
- Comprehensive review of existing literature on estrogen, aging, and atherosclerosis.
- Analysis of molecular mechanisms linking estrogen, senescence, and vascular health.
- Discussion of potential therapeutic interventions targeting aging and hormonal pathways.
Main Results:
- Estrogen deficiency and aging create a pathogenic loop exacerbating AS.
- Understanding the synergistic or sequential effects of estrogen and aging is crucial.
- Sex-specific aging trajectories may modulate AS risk.
Conclusions:
- Integrating aging interventions (e.g., senolytics) with precise estrogen replacement is a promising therapeutic strategy.
- Future research should focus on longitudinal studies and tissue-selective estrogen analogs.
- A dual-pathway approach addressing hormonal deficits and cellular senescence may overcome limitations of current therapies.
Abstract:
Atherosclerosis (AS) poses a substantial risk to human health, leading to serious cardiovascular and cerebrovascular incidents, such as myocardial infarction, coronary heart disease, and ischemic shock. The treatment and control of AS are challenging because of its complex pathogenesis and multiple risk factors. Notably, changes in the estrogen levels and aging are associated with the formation and progression of AS because of their involvement in lipid metabolism, inflammatory responses, coagulation and fibrinolytic systems. Emerging evidence suggests that estrogen modulates vascular senescence pathways, whereas aging exacerbates endothelial dysfunction induced by estrogen deficiency, thereby establishing a bidirectional pathogenic loop. However, the precise interplay between estrogen and aging in AS pathogenesis remains uncertain, particularly regarding whether their effects are synergistic or sequential, and how sex-specific aging trajectories influence this relationship. In this review, In this review, we provide a comprehensive analysis of the interplay among estrogen, aging, and AS, thereby laying the foundation for developing novel therapeutic approaches to AS management. We propose the integration of targeted aging interventions, such as the elimination of senescent cells or the inhibition of senescence-associated secretory phenotype (SASP), with refined estrogen replacement strategies that account for therapeutic timing, receptor subtype specificity, and aging-related vascular microenvironment changes. Future research should prioritize longitudinal studies to delineate estrogen-aging interactions during the menopausal transition, develop tissue-selective estrogen analogs, and design combinatorial therapies targeting hormonal deficits and cellular senescence. This dual-pathway strategy may overcome limitations of conventional estrogen replacement therapies while addressing the root causes of age-exacerbated AS pathogenesis.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Inflammation
Coronary Artery Disease I: Introduction
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis IV: Nursing Management

